Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes

Drug Design Development and Therapy, Год журнала: 2025, Номер Volume 19, С. 1795 - 1808

Опубликована: Март 1, 2025

Aim: The aim of this study was to compare the efficacy and safety fixed-dose combination (FDC) pioglitazone metformin supplemented with dapagliflozin (test group) those basal insulin (control in patients inadequately controlled type 2 diabetes mellitus (T2DM). Methods: This 16-week, prospective, randomized, open-label enrolled aged 18– 75 years glycated hemoglobin (HbA1c) levels between ≥ 8% ≤ 11%. primary endpoint proportion who achieved HbA1c < 7% at week 16 without hypoglycemia or weight gain. secondary endpoints included blood glucose, lipid profile, body weight, mass index, inflammatory markers, bone Gla-protein, liver enzymes, patient satisfaction. Results: Among full analysis set 147 participants, no significant difference observed test group control group. However, had a higher percentage experienced loss 3% (31.51% vs 13.51%, P =0.009). Patients whose BMI≥ 24 kg/m also substantial achievement rate (36.73% 15.79%, =0.014). exhibited greater reduction improvements 2-hour postprandial glucose level, systolic pressure, profile. Notably, therapy did not increase risk were more satisfied than continuing accept pioglitazone/metformin FDC combined dapagliflozin. Conclusion: In absence contraindications, may serve as safe effective alternative for rectifying inadequate control, former enables metabolic compromising safety. Chinese Clinical Trial Registry Number: CHiCTR 2000036076 . https://www.chictr.org.cn/showproj.html?proj=58825 Keywords: dapagliflozin, FDC, diabetes, metformin,

Язык: Английский

Research Advances of Metformin-Based Fixed-Dose Combination in the Treatment of Type 2 Diabetes Mellitus

Journal of Clinical Personalized Medicine, Год журнала: 2025, Номер 04(02), С. 240 - 247

Опубликована: Янв. 1, 2025

Язык: Английский

Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials

Diabetes Obesity and Metabolism, Год журнала: 2024, Номер 27(2), С. 953 - 964

Опубликована: Ноя. 28, 2024

This study aimed to build a model-based predictive approach evaluate the gastrointestinal side effects following an initial metformin medication.

Язык: Английский